26/06/2019 – AB Science reports the outcome from the interim analysis of study AB09004 in Alzheimer’s Disease Post navigationPreviousPrevious post:June 14 2019 web conference presentationNextNext post:Validation of the AB8939 clinical development plan through regulatory authority Scientific Advice procedureRelated PostsPublication of new results in in the peer-reviewed journal Glia that further support masitinib’s potential mode of action in ALSDecember 23, 2019Publication of three AB8939 scientific abstracts in the special ASH Annual Meeting issue of BloodDecember 9, 2019Webcast on masitinib in severe asthma on Monday, December 2, 2019November 26, 2019Summary of webcast with Key Opinion Leaders on Indolent Systemic MastocytosisNovember 25, 2019Clarification regarding the article in the newspaper Les Echos related to the investigation by the French market authoritiesNovember 22, 2019Positive top-line Phase 3 results for masitinib in severe asthmaNovember 7, 2019
Publication of new results in in the peer-reviewed journal Glia that further support masitinib’s potential mode of action in ALSDecember 23, 2019
Publication of three AB8939 scientific abstracts in the special ASH Annual Meeting issue of BloodDecember 9, 2019
Clarification regarding the article in the newspaper Les Echos related to the investigation by the French market authoritiesNovember 22, 2019